CD47 and anemia (phenotype): This could potentially be due to the design of the antibodies, as magrolimab also has specific toxicities such as RBC agglutination leading to anemia [10, 13, 64, 65], a concern that was absent with SRF231 and other newer CD47 mAbs [18, 74].